Siemens Fonds Invest GmbH Decreases Stock Position in Qiagen N.V. $QGEN

Siemens Fonds Invest GmbH lessened its stake in shares of Qiagen N.V. (NYSE:QGEN) by 17.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 107,261 shares of the company’s stock after selling 22,569 shares during the quarter. Siemens Fonds Invest GmbH’s holdings in Qiagen were worth $4,824,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Danske Bank A S purchased a new stake in Qiagen during the 3rd quarter valued at $36,000. Smartleaf Asset Management LLC increased its stake in Qiagen by 1,383.3% in the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after purchasing an additional 830 shares during the period. Manchester Capital Management LLC purchased a new stake in Qiagen in the fourth quarter worth $42,000. Global Retirement Partners LLC increased its stake in Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after purchasing an additional 851 shares during the period. Finally, Allworth Financial LP increased its stake in Qiagen by 23.2% in the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock worth $61,000 after purchasing an additional 256 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on QGEN shares. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $43.00 target price on shares of Qiagen in a research note on Thursday, April 30th. TD Cowen reiterated a “hold” rating and issued a $40.00 target price (down from $46.00) on shares of Qiagen in a research note on Thursday, May 7th. Zacks Research upgraded Qiagen from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 29th. Robert W. Baird set a $43.00 target price on Qiagen and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $44.98.

Qiagen Stock Performance

QGEN stock opened at $37.21 on Wednesday. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. The business’s fifty day simple moving average is $36.91 and its two-hundred day simple moving average is $43.80. Qiagen N.V. has a twelve month low of $32.53 and a twelve month high of $57.81. The firm has a market cap of $7.67 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 3.68 and a beta of 0.66.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, meeting the consensus estimate of $0.54. The firm had revenue of $492.32 million for the quarter, compared to analyst estimates of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same quarter last year, the firm posted $0.56 earnings per share. Analysts predict that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The company also recently declared an annual dividend, which will be paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th will be paid a dividend of $0.35 per share. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 104.0%. The ex-dividend date is Tuesday, July 7th. Qiagen’s payout ratio is 13.61%.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.